Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Karolyn A. Oetjen, MD, Diane E. Bender, PhD, Marianna B. Ruzinova, MD PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 3728.

https://doi.org/10.1182/blood-2019-127460

Published: 2019

Journal Articles

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Sarah K Johnson, PhD, Stephen Burke, PhD, Matthew Henry, M.S., Amy Greenway, Katie Stone, BS, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4466.

https://doi.org/10.1182/blood-2018-99-119241

Published: 2018

Journal Articles

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Jonas Paludo, MD, Jose Villasboas Bisneto, MD, Anne J Novak, PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Esteban Braggio, PhD, Craig B. Reeder, MD, Shahrzad Jalali, PhD, Francis K. Buadi, MB, CHB, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2018-99-117568

Published: 2018

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status

Guopan Yu, MD, PhD, Weiguo Zhang, MD PhD, Charlie Ly, BS, Hongying Zhang, MD, William Rice, PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 4629.

https://doi.org/10.1182/blood.V130.Suppl_1.4629.4629

Published: 2017

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Naveen Pemmaraju, MD, Kenneth Vaughan, Sherry Pierce, BSN, BA, Marina Konopleva, MD PhD, Tapan Kadia, MD, Courtney DiNardo, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Adam R Craig, MD PhD, Farhad Ravandi, MD

Blood (2015) 126 (23): 461.

https://doi.org/10.1182/blood.V126.23.461.461

Published: 2015

Journal Articles

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel Russell, Robert K. Hills, Claire Hemmaway, Nicki Panoskaltsis, Mary-Frances McMullin, Lars Kjeldsen, Helen Dignum, Ian F. Thomas, Richard E. Clark, Don Milligan, Alan K. Burnett

Blood (2015) 125 (19): 2923–2932.

https://doi.org/10.1182/blood-2014-10-608117

Published: 2015

Includes: Supplemental data

Journal Articles

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Blood (2011) 117 (7): 2137–2145.

https://doi.org/10.1182/blood-2010-08-301713

Published: 2011

Includes: Supplemental data

Journal Articles

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.

Harry P Erba, Margaret O'Donnell, Steven L Allen, Maria R Baer, Bayard L Powell, Richard M Stone, John M Bennett, Ante S Lundberg, Robert L Capizzi, David A Rizzieri

Blood (2009) 114 (22): 1047.

https://doi.org/10.1182/blood.V114.22.1047.1047

Published: 2009

Journal Articles

Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML

Steven L Allen, Harry P Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S Lundberg, John M Bennett, Robert L Capizzi

Blood (2008) 112 (11): 2968.

https://doi.org/10.1182/blood.V112.11.2968.2968

Published: 2008

Journal Articles

Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia : Single-Center Experience

Hwa Jung Sung, MD, PhD, Eui Bae Kim, MD, Se Ryeon Lee, MD, PhD, Hee Yun Seo, MD, Kyong Hwa Park, MD, PhD, In keun Choi, MD, PhD, Sang Chul Oh, MD, PhD, Chul Won Choi, MD, PhD, Byung Soo Kim, MD, PhD, Yeul Hong Kim, MD, PhD, Jun Suk Kim, MD, PhD

Blood (2008) 112 (11): 4007.

https://doi.org/10.1182/blood.V112.11.4007.4007

Published: 2008

Journal Articles

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Kieran L. O’Loughlin, BS, Hans Minderman, PhD, Laurie A. Ford, BS, Maria R. Baer, MD

Blood (2007) 110 (11): 2380.

https://doi.org/10.1182/blood.V110.11.2380.2380

Published: 2007

Journal Articles

Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.

Richard R. Furman, MD, Nancy L. Bartlett, M.D., Alvin F. Wong, Pharm.D., Leanne M. McCulloch, Pharm.D., Gilbert N. Lam, Ph.D., Todd Rosenthal, Ian Flinn, M.D., John P. Leonard, M.D.

Blood (2006) 108 (11): 2429.

https://doi.org/10.1182/blood.V108.11.2429.2429

Published: 2006

Journal Articles

Cell Cycle Progression and Self-Renewal Divisions of Cord Blood Derived CD34+ Cells Treated with the Polyamine Copper-Chelator Tetraethylenepentamine.

Toni Peled, Noga R. Goudsmid, Frida Grynspan, Sophie Adi, Efrat Landau, Arnon Nagler, Eitan Fibach, Yaron Daniely

Blood (2004) 104 (11): 4237.

https://doi.org/10.1182/blood.V104.11.4237.4237

Published: 2004

NARROW

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.

Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML

Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia : Single-Center Experience

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.

Cell Cycle Progression and Self-Renewal Divisions of Cord Blood Derived CD34+ Cells Treated with the Polyamine Copper-Chelator Tetraethylenepentamine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only